Evidence map›Paper›PMID 21084309›Full record

ArticleThe Journal of biological chemistry2011

The role of Cys-298 in aldose reductase function.

Ganesaratnam K Balendiran, Michael R Sawaya, Frederick P Schwarz, Gomathinayagam Ponniah, Richard Cuckovich, Malkhey Verma, Duilio Cascio

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ganesaratnam K BalendiranDepartment of Chemistry, Youngstown State University, Youngstown, Ohio 44555, USA. gkbalendiran@ysu.edu
Michael R Sawaya
Frederick P Schwarz
Gomathinayagam Ponniah
Richard Cuckovich
Malkhey Verma
Duilio Cascio
Youngstown State University · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USNational Institute of Standards and Technology · USUniversity of Manchester · GB

Funding

Role of fibrate mechanism in diabetes and its complicationsR15DK085496 · NIDDK · YOUNGSTOWN STATE UNIVERSITY · PI BALENDIRAN, GANESARATNAM · 2010 to 2017
$491k
NIDDK NIH HHS DK085496NIDDK NIH HHS R15 DK085496
6 · The paper itself

Abstract

Diabetic tissues are enriched in an "activated" form of human aldose reductase (hAR), a NADPH-dependent oxidoreductase involved in sugar metabolism. Activated hAR has reduced sensitivity to potential anti-diabetes drugs. The C298S mutant of hAR reproduces many characteristics of activated hAR, although it differs from wild-type hAR only by the replacement of a single sulfur atom with oxygen. Isothermal titration calorimetry measurements revealed that the binding constant of NADPH to the C298S mutant is decreased by a factor of two, whereas that of NADP(+) remains the same. Similarly, the heat capacity change for the binding of NADPH to the C298S mutant is twice increased; however, there is almost no difference in the heat capacity change for binding of the NADP(+) to the C298S. X-ray crystal structures of wild-type and C298S hAR reveal that the side chain of residue 298 forms a gate to the nicotinamide pocket and is more flexible for cysteine compared with serine. Unlike Cys-298, Ser-298 forms a hydrogen bond with Tyr-209 across the nicotinamide ring, which inhibits movements of the nicotinamide. We hypothesize that the increased polarity of the oxidized nicotinamide weakens the hydrogen bond potentially formed by Ser-298, thus, accounting for the relatively smaller effect of the mutation on NADP(+) binding. The effects of the mutant on catalytic rate constants and binding constants for various substrates are the same as for activated hAR. It is, thus, further substantiated that activated hAR arises from oxidative modification of Cys-298, a residue near the nicotinamide binding pocket.

Indexed as

Aldehyde ReductaseAmino Acid SubstitutionCatalytic DomainCrystallography, X-RayCysteineDiabetes MellitusEnzyme ActivationHumansHydrogen BondingMutation, MissenseNADPOxidation-ReductionProtein Structure, TertiaryAldehyde ReductaseCysteineNADP

Identifiers

PMID21084309
PMCPMC3057803
OpenAlexW2162502716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.